Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Inhibrx Biosciences, Inc.

Inhibrx Biosciences Inc ( ($INBX) ) has provided an announcement. On September 8, 2026, Inhibrx Biosciences reported primary endpoint data from the...

Inhibrx Biosciences reports strong Phase 2 INBRX-106 data

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on First Horizon (FHN) and Inhibrx Biosciences Inc (INBX) with ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INBX	$99.61	-0.79%	158.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INBX	$99.61	-0.8%	158.66K
3
4
5
6

INBX

Get Inhibrx Biosciences, Inc. Data in Excel

Get Inhibrx Biosciences, Inc. Data in Excel